Cellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays reduced their price objective on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th.

Cellectis Trading Down 1.1 %

Shares of Cellectis stock opened at $1.80 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. The business has a fifty day simple moving average of $1.84 and a two-hundred day simple moving average of $2.01. Cellectis has a 1 year low of $1.41 and a 1 year high of $3.38. The company has a market capitalization of $100.05 million, a price-to-earnings ratio of -1.38 and a beta of 3.09.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The company had revenue of $18.05 million for the quarter, compared to analyst estimates of $5.00 million. During the same quarter in the prior year, the business posted ($0.31) EPS. Research analysts forecast that Cellectis will post -0.46 EPS for the current year.

Institutional Trading of Cellectis

Several hedge funds and other institutional investors have recently bought and sold shares of CLLS. Long Focus Capital Management LLC increased its holdings in shares of Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares during the period. Principal Financial Group Inc. grew its position in Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after buying an additional 12,467 shares in the last quarter. First Affirmative Financial Network acquired a new stake in Cellectis during the third quarter worth approximately $45,000. Finally, XTX Topco Ltd bought a new position in Cellectis during the 2nd quarter worth $29,000. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.